Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, ViroGates announced a deal with Sobi, Evaxion announced positive phase I results using its AI technology, and one management team sold more than 75 MDKK worth of shares.
10 of the 20 listed, Danish biotech companies have published news the past week. 8 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Curasight continue to be the best performing stock this year.
Company news the past week
Ascendis Pharma
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates (Link)
Wedbush raises price target to $187.
Biosergen publishes interim report for first quarter 2023 (Link)
Cessatech
Cessatech provides positive news regarding shelf life of CT001 (Link)
No news the past week
No news the past week
Evaxion Biotech
Evaxion Announces Business Update and First Quarter 2023 Financial Results (Link)
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial (Link)
Expres2ion
No news the past week
Fluoguide
FluoGuide A/S publishes interim report for the period January – March 2023 (Link)
Genmab
Genmab’s CEO and CFO sold shares for a total of 75 MDKK.
Gubra
No news the past week
Initiator Pharma
Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine (Link)
IO Biotech
IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (Link)
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
No news the past week
SynAct Pharma
SynAct Pharma to present at the 2023 BIO International Convention (Link)
ViroGates
ViroGates announces an agreement with Sobi for the development of suPARnostic® for commercial use in the US in combination with Sobi’s Kineret® treatment for COVID-19-related pneumonia (Link)
Zealand Pharma
No news the past week
Y-mAbs Therapeutics
No news the past week
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was -0.6%. Saniona rose 19% without any company news. ViroGates also performed well towards the end of the week following the deal with Sobi. On the other hand, 2Curex AB and Y-mAbs Therapeutics Inc. fell the most by 6-10%. Year to date a few companies have delivered excellent returns. Curasight A/S, Fluoguide A/S and Saniona AB have risen by 125-141% after among other things partnerships and positive recommendations paving the way for approvals.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
